Notably, the administered neratinib dose considerably deviated from current clinical standards, providing an innovative perspective on a potent, well-tolerated, and enhanced treatment strategy for HR+/HER2-low breast cancer, extending beyond CDK4/6 inhibitors combined with endocrine therapy. This evidence concerns the gene ERBB2 and breast cancer.